Applied dna announces fourth quarter and fiscal year 2024 financial results, announces strategic restructuring to prioritize the manufacture of critical starting materials for genetic medicines

- pursuing divestiture of certaint® platform, implements changes to corporate leadership - - build-out of gmp manufacturing facility to be completed by january 9, 2025 - - webcast and conference call scheduled for thursday, january 9, 2025, at 4:30 pm et - stony brook, ny / accesswire / december 17, 2024 / applied dna sciences, inc. (nasdaq:apdn) ("applied dna" or the "company"), a leader in pcr-based dna technologies, today reported financial results for its fourth quarter and fiscal year ended september 30, 2024. an update on the buildout of the company's gmp manufacturing facility is available for viewing via slideshow on the presentations page of the investor relations portion of the company's website.
APDN Ratings Summary
APDN Quant Ranking